SAN DIEGO and VANCOUVER, British Columbia, Aug. 10, 2017 /PRNewswire/ -- Sophiris Bio Inc. (NASDAQ: SPHS) (the “Company” or “Sophiris”), a late stage clinical biopharmaceutical company developing topsalysin (PRX302) for the treatment of patients with urological diseases, today reported financial results for the three and six months ended June 30, 2017 and key corporate highlights.
Key Corporate Highlights:
Phase 2b Localized Prostate Cancer Study Underway.
